Original Research Article

Five years trend of bacteriological profile and antibiogram of urinary tract infections at a rural medical college hospital in North Kerala, India: 2012-16

Ramakrishna Pai J1, Sumita Rajeevan1,*, Syed Mustaq Ahmed1, Ann Taisy George2, Preethy Edavaloth1, Rajeevan V3

1 Dept. of Microbiology, MES Medical College and Hospital, Perinthalmann, Kerala, India
2 Dept. of Microbiology, Al Azhar Medical College, Thodupuzha, Kerala, India
3 Dept. of General Medicine, Nila Hospital, Pattambi, Kerala, India

A R T I C L E  I N F O

Article history:
Received 18-01-2020
Accepted 27-03-2020
Available online 20-07-2020

Keywords:
Urinary tract infections
Antibiotic resistance patterns
Bacteriological profile

A B S T R A C T

Background and Objective: Urinary tract infections (UTI) are amongst the most common bacterial infections in developing countries. The etiology of UTI and the antibiotic resistance of uropathogens vary in regions and change through times. Regular surveillance of the changing trends in its bacteriological profile and antibiotic sensitivity pattern is therefore mandatory. This study aims to find out the changing trends in the prevalence and antibiotic susceptibility patterns of urinary isolates of over five consecutive years.

Materials and Methods: A retrospective, record based study was conducted on all culture and sensitivity (C/S) reports of urine samples obtained in the microbiology laboratory in a tertiary care centre, Central Kerala (January 2012- December 2016). The C/S reports which were positive for significant growth were analyzed to find out its prevalence and antibiotic susceptibility patterns. Descriptive statistics was used for data analysis and the results were expressed in percentages.

Result: Of the 14105, urine specimens received, 27.93% were positive. Highest rate of UTI is seen in female patients (67.58%) and geriatric age group 47.58%. E.coli and Klebsiella are the two most common isolates from all five years of study period and constituted ~72% of total. The year wise analysis of antibiotic resistance showed fluctuating pattern. The resistance rate to drugs like Piperacillin –tazobactam and carbepenem showed increasing drug resistance. E.coli was found to be more sensitive to Amikacin and nitrofurantoin.

Conclusion: Drug resistant strains are markedly high in our area. Antibiotic resistance does not show a consistent trend over years and vary from region to region. Therefore each institution should have an antibiotic policy based on the local antibiogram which is to be renewed regularly.

© 2020 Published by Innovative Publication. This is an open access article under the CC BY-NC license (https://creativecommons.org/licenses/by-nc/4.0/)

1. Introduction

Urinary tract infections (UTIs) constitute a major burden of bacterial infections world over. It accounts for approximately 150 million cases annually. Apart from being the most common cause of nosocomial infection among hospitalized patients, it is also the second most common cause of hospital visit. UTI are a significant cause of morbidity in elderly people, and in females of all ages. Of the various uropathogens, the Gram-negative bacteria such as Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, and Acinetobacter species cause most of the UTIs, and Gram-positive bacteria such as Enterococcus species and Staphylococcus species also contribute to causing UTIs. E.coli is the most common cause of both community acquired and hospital acquired cases. Inappropriate and empirical usage of wide spectrum antibiotics, immunosuppression and prolonged hospitalization are some of the major factors that elevate the chances of infection. Treatment becomes even more
challenging in the presence of risk factors such as old age, comorbidity, and immunocompromised state. The antibiotic susceptibility pattern of uropathogens varies with types of organism, different environments and geographical locations. Therefore periodic evaluation of changing trends in the etiology and resistance pattern is necessary to update this information. The present study is carried out with the aim of finding out rate of UTI and distribution of urinary isolates in different age and sex groups and their antibiotic susceptibility pattern in a tertiary care centre in North Kerala, India.

2. Materials and Methods

A retrospective study was conducted in the Department of Clinical Microbiology, of 570-bedded multispeciality medical college hospital in North Kerala after clearance from the Institutional Ethics Committee (No. IEC/MES/26/2017). This study was conducted with an objective to determine the etiological bacterial pathogens of the Urinary tract infection and the antibiotic susceptibility pattern of pathogens isolated.

All the positive urine culture samples of outpatients and inpatients above the age of 18 years, who were suspected of urinary tract infection from January 2012 to December 2016, were included in the study. Samples included in the study were midstream clean catch urine, urine from a patient with an indwelling catheter and suprapubic/cystoscopic aspiration. All samples collected were immediately transported to the Diagnostic Microbiology Department and processed within 2 hour. All urine samples were inoculated onto cysteine lactose electrolyte deficient (CLED) medium (Himedia, Mumbai, India) using a calibrated loop (volume-0.005 ml) and were incubated for 18-24 h at 37°C. Samples showing significant growth, bacteria growing >10^5 colony-forming units (CFU/mL) with single morphotype or up to 2 types, were considered significant and processed further for identification and susceptibility testing. Gram-positive organisms were processed, if isolated as pure growth even when the colony counts were <10^4 CFU/mL. Susceptibility testing was done by Kirby-Bauer disk diffusion method and interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. The quality control of the disc was tested by Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923.

The demographic details of the patients, the pathogen isolated and the antibiotic susceptibility pattern were collected. All samples were stratified by year, gender, ward and age wise (18–30, 31–45, 46–60 and >60 years). The year-wise cumulative antibacterial resistance rate was calculated for Gram-positive and Gram-negative organisms separately and analysed for change in the rate. The collected data were entered into Microsoft Excel and analysed.

3. Result

During the study period from January 2012 to December 2016, a total of 14,105 urine samples were received in our lab. Of these, 3939 (27.93%) were positive. Among the positive cultures, 32.42% were from male patients and 67.58% from female patients. In the ward wise distribution 48.84%, 41.08% and 10.08% the positive samples were from outpatients, Inpatients and high risk areas respectively. The geriatric patients above 61 years constituted 47.78% of the positive samples. The details of positive samples with regard to sex, ward and age group is given in detail in Table 1.

Of 3939 pathogens isolated, the gram negative bacteria constituted for 3572 (90.68%), Enterobacteriaceae spp. constituted 3171 (80.50%). Among them Escherichia coli, Klebsiella sp, Citrobacter sp, and Proteus sp accounted for 52.53%, 19.62%, 7.31% and 1.04% respectively. Non fermenter Gram negative bacilli were 401(10.18%), Pseudomonas spp (295, 7.49%) and Acinetobacter sp (106, 2.69%). The gram positive bacteria constituted for 296 (7.51%), Enterococcus sp (196, 4.98%) and Staphylococcus sp accounted for 100 (2.54%). Fungus Candida sp. constituted 71 (1.80%). It is given in detail in Table 2.

Among all the isolated uropathogens in female patients the prevalence rate of Escherichia coli was 72.21%, followed by Klebsiella sp. 65.20%, Pseudomonas sp. 58.64%, Proteus sp. 58.54%, Citrobacter sp. 58.33% where as in male patients Acinetobacter sp. was isolated in 47.1% of cases followed by staphylococcus sp. 42%, Citrobacter sp. 41.67% given in Table 3.

The antimicrobial resistance spectrum assessment revealed that in Enterobacteriaceae isolates, there was a steady rise in resistance for 3rd generation Cephalosporins (3GC) till the year 2014 followed by an increase in sensitivity in 2015 and 2016. Gentamycin resistance steadily declined from 2012 to 2016. Amikacin resistance was highest in 2014 except for proteus sp. which showed
Table 1: Demographic details of the Urine Sample received during the study period (2012-16)

|        | 2012  | 2013  | 2014  | 2015  | 2016  | Total Number | Percentage |
|--------|-------|-------|-------|-------|-------|--------------|------------|
| Total sample | 3207  | 3329  | 3432  | 3615  | 3729  | 14105        |            |
| Positive | 638   | 779   | 653   | 832   | 1037  | 3939         |            |
| Gender  |       |       |       |       |       |              |            |
| Male    | 210.0 | 226.0 | 195   | 286   | 360   | 1277         | 32.42      |
| Female  | 428   | 553   | 458   | 546   | 677   | 2662         | 67.58      |
| Age     |       |       |       |       |       |              |            |
| 18-30   | 89    | 122   | 121   | 111   | 144   | 587          | 14.90      |
| 31-45   | 98    | 110   | 85    | 115   | 126   | 534          | 13.56      |
| 46-60   | 133   | 183   | 144   | 207   | 269   | 936          | 23.76      |
| 61-75   | 238   | 255   | 222   | 274   | 372   | 1361         | 34.55      |
| >75     | 80    | 109   | 81    | 125   | 126   | 521          | 13.23      |
| Ward    |       |       |       |       |       |              |            |
| OP      | 237   | 363   | 328   | 393   | 603   | 1924         | 48.84      |
| IP      | 326   | 326   | 268   | 362   | 336   | 1618         | 41.08      |
| HRA     | 75    | 90    | 57    | 77    | 98    | 397          | 10.08      |

Table 2: Year-wise distribution of the Pathogens Isolated from the urine during the study period.(in %)

| Gram negative bacteria | 2012 | 2013 | 2014 | 2015 | 2016 | Total | %    |
|------------------------|------|------|------|------|------|-------|------|
| **Enterobacteriaceae** |      |      |      |      |      |       |      |
| *Escherichia coli*     | 366  | 414  | 355  | 420  | 514  | 3171  | 80.50|
| *Klebsiella sp*        | 114  | 164  | 125  | 173  | 197  | 773   | 19.62|
| *Citrobacter sp*       | 65   | 51   | 56   | 48   | 68   | 288   | 7.31 |
| *Proteus sp*           | 4    | 11   | 5    | 9    | 12   | 41    | 1.04 |
| **Non fermentor GNB**  |      |      |      |      |      | 401   | 10.18|
| *Pseudomonas sp*       | 41   | 63   | 49   | 57   | 85   | 295   | 7.49 |
| *Acinetobacter sp*     | 14   | 16   | 9    | 20   | 47   | 106   | 2.69 |
| **Gram positive bacteria** |      |      |      |      |      |       |      |
| *Enterococcus sp*      | 20   | 50   | 27   | 54   | 45   | 196   | 4.98 |
| *Staphylococcus sp*    | 14   | 10   | 9    | 30   | 37   | 100   | 2.54 |
| **Fungus**             |      |      |      |      |      |       |      |
| *Candida sp*           | 638  | 779  | 653  | 832  | 1037 | 3939  | 100.00|
steady rise in resistance pattern till 2016. The beta lactam-beta lactamase inhibitor (PT) resistance has increased in Proteus sp., Klebsiella sp., Citrobacter sp., steadily. There was no resistance observed for meropenem in the first two years (2012, 2013), in all the isolates of enterobacteriaceae and non fermenter gram negative bacilli but later years showed emergence of resistance which gradually increased till 2016 (Tables 4 and 5).

The gram positive cocci showed increase in resistance to ampicillin and amoxyclav, but resistance pattern of ciprofloxacin was highest in 2012 and it gradually decreased by 2016. During the study period, we have not encountered any resistance to Vancomycin, Linezolid and Teicoplanin. We have observed increase in resistance to Amikacin over 5 years for Staphylococcus sp.

We observed that the Acinetobacter spp has emerged as a Multi –drug resistant pathogen, with increasing resistance to 3GC, Amikacin, Piperacillin Tazobactum and Meropenem to 97.87%, 23.40%, 38.30% and 80.85% respectively. Similar, trend was observed in Pseudomonas spp., E.coli and Klebsiella sp with increased resistance to these drugs (Tables 4 and 5).

4. Discussion

Continuous survey of antimicrobial resistance (AMR) plays an important role in the empiric treatment of UTI. Although AMR is rising all over the world, there is a significant difference in the resistance pattern across different geographical areas and also susceptibility of uropathogens varies with time. It is therefore important to keep a continuous record of the rates of AMR in the clinically important pathogens at various regions across the world.

The present study reports a prevalence rate of 27.9% among the patients suspected of having UTIs. Similar prevalence rates have been reported by Indian authors 22.78% and 32%. However a study from north India done reported a higher prevalence of Gram-negative bacillus, followed by Klebsiella species(20%) and Pseudomonas species (7.5%) which is consistent with many other studies. Our most common isolate E. coli was 52.53% the rate is less compared to western studies where it was 85% but similar to other Indian studies. Enterobacteriace have several factors responsible for their attachment to the uroepithelium. These bacteria colonize the urogenital mucosa with adhesin, pili, fimbriae and P1-blood group phenotype receptor making them the most commonly isolated organisms.

Among gram positive isolates Enterococcus sp. is the most common isolated organism (5%), followed by S. aureus (2.54%), which is consistent with other study. However, studies from other parts of the country have shown different isolation rates, probably due to variation in geographical location or population. While the study from north India done reported a higher prevalence of gram positive isolates (21.79%). Non-fermenters are ubiquitous in the environment, able to survive in the hospital environment and can spread among hospitalized patients. They are emerging nosocomial pathogens especially in seriously ill patients and are responsible for causing a variety of infections. We have seen an upward trend in its isolation from 2012 to 2016.

Antimicrobial resistance all over the world is on rise and isolates from our study were resistant to multiple drugs. Also resistance pattern varies with time which makes it difficult to start a desired treatment. Most of the isolates were resistant to multiple antibiotics at our setting. E.coli

**Table 3: Gender wise prevalence of uropathogens**

| Gender  | Male      | Female     | Total |
|---------|-----------|------------|-------|
| E.coli  | 575 (27.79%) | 1494 (72.21%) | 2069  |
| Klebsiella sp | 269 (34.80%)  | 504 (65.20%) | 773   |
| Citrobacter sp | 120 (41.67%)  | 168 (58.33%) | 288   |
| Proteus sp  | 17 (41.46%)  | 24 (58.54%)  | 41    |
| Pseudomonas sp | 122 (41.36%) | 173 (58.64%) | 295   |
| Acinetobacter sp | 50 (47.17%)   | 56 (52.83%)  | 106   |
| Enterococcus sp | 56 (28.57%)   | 140 (71.43%) | 196   |
| Staphylococcus sp | 42 (42.00%)   | 58 (58.00%)  | 100   |
| Organism/antibiotics | 2012 | 2013 | 2014 | 2015 | 2016 | Average |
|----------------------|------|------|------|------|------|---------|
| *Escherichia coli* (2069) |      |      |      |      |      |         |
| Ampicillin           | 97.27| 95.17| 93.52| 93.57| 89.49| 93.80   |
| Amoxyclav            | 76.78| 73.91| 90.99| 96.90| 95.14| 86.74   |
| 3GC                  | 75.14| 76.57| 81.41| 78.57| 75.49| 77.43   |
| Cotrimoxazole        | 61.75| 68.84| 61.97| 62.14| 57.98| 62.53   |
| Gentamicin           | 61.20| 47.83| 34.37| 33.81| 25.49| 40.55   |
| Amikacin             | 13.66| 11.11| 16.06| 11.67| 15.37| 13.57   |
| Ciprofloxacin        | 83.88| 75.85| 72.11| 70.95| 64.20| 73.4    |
| Piperacillin         | 0.00 | 9.90 | 56.34| 62.14| 64.9  | 38.65   |
| Tazobactum           |      |      |      |      |      |         |
| Meropenem            | 0.00 | 0.00 | 22.25| 43.8 | 46   | 22.41   |
| Nitrofurantoin       | 30.33| 23.43| 22.25| 20.00| 41.83| 27.56   |
| *Klebsiella sp* (773) |      |      |      |      |      |         |
| 3GC                  | 79.82| 76.83| 91.20| 94.80| 100.00| 88.53   |
| Cotrimoxazole        | 71.05| 59.76| 61.60| 55.49| 54.31| 60.44   |
| Gentamicin           | 65.79| 53.66| 38.40| 39.31| 38.58| 47.14   |
| Amikacin             | 20.18| 21.95| 24.00| 22.54| 25.89| 22.91   |
| Ciprofloxacin        | 79.82| 64.63| 65.60| 52.02| 58.88| 64.19   |
| Piperacillin         | 0.00 | 23.78| 67.20| 43.93| 39.5  | 34.88   |
| Tazobactum           |      |      |      |      |      |         |
| Meropenem            | 0.00 | 0.00 | 29.60| 22.54| 23.35| 15.09   |
| *Citrobacter sp* (289) |    |     |     |     |     |         |
| 3GC                  | 66.15| 62.75| 57.14| 60.42| 55.88| 60.46   |
| Gentamicin           | 63.08| 47.06| 44.64| 37.50| 42.65| 46.98   |
| Amikacin             | 27.69| 23.53| 32.14| 25.00| 20.59| 25.79   |
| Ciprofloxacin        | 78.46| 58.82| 69.64| 60.42| 60.29| 65.52   |
| Piperacillin         | 0.00 | 13.73| 67.86| 43.75| 39.5  | 40.65   |
| Tazobactum           |      |      |      |      |      |         |
| Meropenem            | 0.00 | 0.00 | 7.14 | 10.41| 50   | 13.51   |
| Nitrofurantoin       | 52.31| 52.94| 57.14| 60.42| 54.41| 55.44   |
| *Proteus sp* (38)    |      |      |      |      |      |         |
| 3GC                  | 75.00| 100.00| 100.00| 77.78| 66.67| 83.89   |
| Gentamicin           | 75.00| 81.82| 100.00| 44.44| 100.00| 70.25   |
| Amikacin             | 50.00| 36.36| 80.00| 44.44| 33.33| 53.82   |
| Ciprofloxacin        | 75.00| 36.36| 80.00| 22.22| 22.22| 47.16   |
| Piperacillin         | 0.00 | 9.09 | 0.00 | 11.11| 22.22| 8.4     |
| Tazobactum           |      |      |      |      |      |         |
| Meropenem            | 0.00 | 0.00 | 0.00 | 0.00 | 11.11| 2.22    |
Table 5: Year-wise Overall Resistance pattern of uropathogens (in %)

| Organism/antibiotics | 2012 | 2013 | 2014 | 2015 | 2016 | Average |
|-----------------------|------|------|------|------|------|---------|
| Pseudomonas sp        |      |      |      |      |      |         |
| (295)                 |      |      |      |      |      |         |
| 3GC                   | 87.80| 36.5 | 89.80| 98.25| 95.29| 81.52   |
| Cotrimoxazole         | 82.93| 73.02| 89.80| 98.25| 85.88| 85.97   |
| Gentamicin            | 56.10| 60.32| 44.90| 38.60| 37.65| 47.51   |
| Amikacin              | 14.63| 36.51| 22.45| 26.32| 34.12| 26.80   |
| Ciprofloxacin         | 75.61| 61.90| 61.22| 45.61| 48.24| 58.51   |
| PiperacillinTazobactum| 0.00 | 12.70| 63.27| 70.17| 84.71| 46.17   |
| Meropenem             | 0.00 | 0.00 | 17   | 35.08| 44.71| 19.35   |
| Acinetobacter sp      | 14   | 16   | 9    | 20   | 47   |         |
| (106)                 |      |      |      |      |      |         |
| Ampicillin            | 100.00| 100.00| 100.00| 100.00| 100.00| 100   |
| 3GC                   | 85.71| 81.25| 66.67| 35.00| 25.53| 57.40   |
| Cotrimoxazole         | 78.57| 81.25| 44.44| 20.00| 31.91| 50.16   |
| Gentamicin            | 42.86| 37.50| 44.44| 15.00| 23.40| 32.64   |
| Amikacin              | 78.57| 75   | 77.78| 75.00| 72.34| 75.73   |
| Ciprofloxacin         | 0.00 | 25.00| 55.56| 75.00| 80.85| 47.28   |
| PiperacillinTazobactum| 0.00 | 0.00 | 11.11| 50.00| 38.30| 19.88   |
| Meropenem             |       |      |      |      |      |         |
| Nitrofurantoin        | 71.43| 62.50| 66.67| 75.00| 55.32| 66.18   |
| Enterococcus sp       | 20   | 50   | 27   | 54   | 45   |         |
| (196)                 |      |      |      |      |      |         |
| Ampicillin            | 35.00| 56.00| 48.15| 42.59| 53.33| 47.01   |
| Amoxycilav            | 30.00| 44.00| 100.00| 98.15| 51.11| 64.65   |
| Gentamicin            | 55.00| 66.00| 48.15| 42.59| 31.11| 48.57   |
| Ciprofloxacin         | 75.00| 72.00| 88.89| 66.67| 42.22| 68.95   |
| Staphylococcus sp     | 14   | 10   | 9    | 30   | 37   |         |
| (100)                 |      |      |      |      |      |         |
| Ampicillin            | 35.71| 60.00| 88.89| 96.67| 89.19| 74.09   |
| Amoxycilav            | 28.50| 20.00| 66.67| 83.33| 83.78| 56.45   |
| 3GC                   | 7.14 | 20.00| 33.33| 83.33| 97.30| 48.22   |
| Cotrimoxazole         | 21.42| 30.00| 44.44| 33.33| 32.43| 32.32   |
| Gentamicin            | 14.27| 20.00| 22.22| 30.00| 21.62| 21.62   |
| Amikacin              | 7.14 | 10.00| 11.11| 16.67| 16.22| 12.22   |
| Ciprofloxacin         | 0.00 | 20.00| 44.44| 43.33| 40.54| 29.66   |

identified in this study were highly resistant to ampicillin (<93%) and amoxyclav (<85%). Studies that were conducted in India by Kothari A et al. showed that the isolates of E.coli showed high resistance towards Ampicillin, amoxyclav which is in agreement with our study. Enterobacteiriae family also offered around 75% resistance towards 3 GC and fluroquinolones while comparatively less resistance to amikacin and gentamycin 13% and 40%. Resistance to fluroquinolones showed a downward trend in last five years. Similar study from central Kerala also documented a decreasing trend over years. In the present study, Amikacin and nitrofurantoin was found to be more sensitive among E.coli. This is similar to other study. There was no resistance to carabepenem in the first two years which slowly increased and in 2016 it was 46%. Multiple mechanisms like production of beta-lactamases, blocking the entry of these antibiotics, or by efflux pumps which actively pump out these antibiotics, have led to rise in the resistance against carabepenems. Carabepenems are often used as the last line of defense against resistant Gram-negative infections and resistance to it could result in higher cost, increased morbidity, mortality and prolonged hospitalization.

The rate of resistance to carabepenem among Gram-negative bacilli seen in our institution could possibly be due to the fact that this is a reference center, and that many of the patients had prior contact with other healthcare institutions and history of antibiotic use.
The limitations of the study were that it was a single centric, retrospective laboratory based and limited to the cases for which cultures were requested from the clinic. Information on antibiotics administered prior to culture or data on subsequent treatment and its outcome in this study population would have added meaningful data to allow a better understanding of the prevalent practice in diagnosis and treatment of UTI.

5. Conclusion
This retrospective study provided information on the common uropathogens and their drug resistance pattern. In this study, high prevalence of UTI was found in female gender and in geriatric patients. *E. coli* (53%) was the most common pathogen causing UTI. The uropathogens showed high levels of resistance to multiple urinary antimicrobial agents leading to limited option of treatment. Empirical Antimicrobials like ampicillin and amoxicillin have developed resistance to such a level that, prescribing them would definitely lead to treatment failure. In order to prevent development of resistance, antibiotic susceptibility patterns must be continuously and periodically evaluated to select the appropriate regimen to treat UTI and to avoid complications. Institutional Antibiotic policy can be tailored to achieve superior therapeutic outcome.

6. Source of Funding
None.

7. Conflict of Interest
None.

References
1. Stamm WE, Norby SR. Urinary Tract Infections: Disease Panorama and Challenges. *J Infect Dis*. 2001;183(s1):S1–S4.
2. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am*. 2014;28:1–13.
3. Raval R, Verma RJ, Kareliya H. ClinicoPathological Features of Urinary Tract Infection in Rural India. *Adv Infect Dis*. 2015;5:132–9.
4. Gupta S, Kapur S, Padmavathi D. Comparative prevalence of antimicrobial resistance in community-acquired urinary tract infection cases from representative States of northern and southern India. *J Clin Diagn Res*. 2014;8:9–12.
5. Kempegowda P, Eshwarappa M, Dosegowda R, Apremaya IV, Khan MW, Kumar PS. Clinico-microbiological profile of urinary tract infection in South India. *Indian J Nephrol*. 2011;21(1):30–6.
6. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing. 21st Informational Supplement, CLSI document M100-S21. Wayne, PA; 2012.
7. Banerjee S. The study of urinary tract infections and antibiogram of uropathogens in and around Ahmadnagar, Maharashtra. *Internet J Infect Dis*. 2009;9:1–5.
8. Murugan K, Savitha T, Vasanthi S. Retrospective study of antibiotic resistance among uropathogens from rural teaching hospital, Tamilnadu, India. *Asian Pac J Trop Dis*. 2012;2(5):375–80.
9. Kumari SS, Ramya T, Reddy K, Swarnalatha G, Swapna V, Reddy BS, et al. Aetiology and antibiotic resistance pattern of uropathogens in a tertiary care hospital. *J Evol Med Dent Sci*. 2016;5(75):5534–8.
10. tuku Nsiale RN, Gonsu HK, Koulla-Shiro S. Bacterial Etiology and Antibiotic Resistance Profile of Community-Acquired Urinary Tract Infections in a Cameroonian City. *Int J Microbiol*. 2016;2016:1–6.
11. Thass N, Kumar M, Kaur R. Prevalence and antibiogram of bacterial pathogens causing urinary tract infection in a tertiary care hospital. *Int J Med Sci Public Health*. 2019;8(1):53–7.
12. Shailaja TS, Mohankumar A. Bacteriological profile of urinary tract infection in a tertiary care centre. *Indian J Microbiol Res*. 2017;4(3):328–32.
13. Ghadge DP, Muley VA, Sharma J, Bhore AV. Bacteriological profile and antibiogram of Urinary TractInfections at a tertiary care hospital. *Nat J Lab Med*. 2016;5(4):20–24.
14. Kalal SBS, Nagaraj. Urinary tract infections: a retrospective, descriptive study of causative organisms and antimicrobial pattern of samples received for culture, from a tertiary care setting. *Germ*. 2016;6(4):132–8.
15. Kaur N, Sharma S, Malhotra S, Madan P, Hans C. Urinary tract infection: aetiology and antimicrobial resistance pattern in infants from a tertiary care hospital in northern India. *J Clin Diag Res*. 2014;8:1–3.
16. Colgan R, Johnson JR, Kuskowski M, Gupta K. Risk Factors for Trimethoprim-Sulfamethoxazole Resistance in Patients with Acute Uncomplicated Cystitis. *Antimicrob Agents Chemother*. 2008;52(3):846–51.
17. Flores-Mirles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol*. 2015;13(5):269–84.
18. Das A, Banerjee T. Prevalence of Urinary Tract Infections and Susceptibility Pattern of Uropathogens in Women of Reproductive age Group from North India. *J Adv Med*. 2015;4(1and2):5.
19. Kothari A, Sagar V. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. *J Infect Dev Ctries*. 2008;2(05):354–62.
20. Regha I. Prevalence and antibiotic susceptibility patterns of pseudomonas aeruginosa in urinary tract infections in a Tertiary care hospital, Central Kerala: A retrospective study over 4 years. *Trop J Path Micro*. 2018;4(1):52–8.
21. Arias CA, Murray BE. Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge. *N Engl J Med*. 2009;360(5):439–43.

Author biography

Ramakrishna Pai J Associate Professor

Sumita Rajeevan Associate Professor

Syed Mustaq Ahmed Professor and HOD

Ann Taisy George Assistant Professor

Preethy Edavaloth Post Graduate cum Tutor

Rajeevan V Consultant Physcian

Cite this article: Pai J R, Rajeevan S, Ahmed SM, George AT, Edavaloth P, Rajeevan V. Five years trend of bacteriological profile and antibiogram of urinary tract infections at a rural medical college hospital in North Kerala, India: 2012-16. *Indian J Microbiol Res* 2020;7(2):175–181.